Enliven Q3 net loss $20.1M; cash $477.6M; Phase 1b enrollment completed for ELVN-001

Enliven Therapeutics, Inc.

2025-Q3 EPS reported -$1.35

Net loss $20.1M in Q3 2025 vs $23.2M in Q3 2024; R&D expenses $18.2M vs $21.3M.
Cash, cash equivalents and marketable securities $477.6M; runway into first half 2029.
Completed randomized Phase 1b portion of ENABLE trial evaluating ELVN-001 in CML patients.
On track to initiate Phase 3 pivotal trial for ELVN-001 in 2026.
Data from ELVN-001 in CML patients with atypical fusion transcripts to be presented at ASH 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.